Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of PXL 770 in healthy volunteers

Trial Profile

A phase I study of PXL 770 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PXL 770 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Proof of concept
  • Sponsors Poxel
  • Most Recent Events

    • 27 Jan 2017 According to a Poxel media release, the company anticipates to continue the study during the second half of this year.
    • 15 Sep 2016 According to a Poxel media release, during the study the company observed a different metabolic pattern in humans compared to animals that were treated with PXL770. Therefore, based on regulatory guidelines, Poxel will need to further evaluate the profile of the metabolites, prior to starting the second part of the phase I study. As a result of this additional preclinical work, the start of the second part of the Phase Ib study will be delayed until 2017.
    • 20 Jun 2016 Results from the first stage of the study (n=64) published in a Poxel media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top